Paper23882157
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
von Boehmer L and 12 others. Cancer Immun, 2013. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Papers, record 23882157. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23882157
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Melanoma | Major topic |
| Membrane Proteins | Major topic |
| Humans | |
| Immunohistochemistry | |
| Male | |
| Middle Aged |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17294444 | NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. | Int J Cancer | 2007 | https://conductscience.org/library/papers/17294444 | PubMed |
| 2 | 17008531 | Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. | Science | 2006 | https://conductscience.org/library/papers/17008531 | PubMed |
| 3 | 7895156 | Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. | Immunity | 1994 | https://conductscience.org/library/papers/7895156 | PubMed |
| 4 | 11027314 | Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. | Proc Natl Acad Sci U S A | 2000 | https://conductscience.org/library/papers/11027314 | PubMed |
| 5 | 9139833 | Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. | Int J Cancer | 1997 | https://conductscience.org/library/papers/9139833 | PubMed |
| 6 | 19381944 | Autoantibodies against cancer antigens. | Methods Mol Biol | 2009 | https://conductscience.org/library/papers/19381944 | PubMed |
| 7 | 10502728 | Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. | Int J Cancer | 1999 | https://conductscience.org/library/papers/10502728 | PubMed |
| 8 | 17652518 | Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17652518 | PubMed |
| 9 | 21754986 | MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. | PLoS One | 2011 | https://conductscience.org/library/papers/21754986 | PubMed |
| 10 | 9618514 | Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9618514 | PubMed |
| 11 | 21436444 | Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. | Science | 2011 | https://conductscience.org/library/papers/21436444 | PubMed |
| 12 | 10781081 | Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. | Proc Natl Acad Sci U S A | 2000 | https://conductscience.org/library/papers/10781081 | PubMed |
| 13 | 18026089 | Adaptive immunity maintains occult cancer in an equilibrium state. | Nature | 2007 | https://conductscience.org/library/papers/18026089 | PubMed |
| 14 | 9636188 | Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9636188 | PubMed |
| 15 | 12445278 | Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. | Immunol Rev | 2002 | https://conductscience.org/library/papers/12445278 | PubMed |
| 16 | 15252201 | Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. | Proc Natl Acad Sci U S A | 2004 | https://conductscience.org/library/papers/15252201 | PubMed |
| 17 | 18833002 | Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. | J Immunother | 2008 | https://conductscience.org/library/papers/18833002 | PubMed |
| 18 | 17944437 | LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. | Cancer Immun | 2007 | https://conductscience.org/library/papers/17944437 | PubMed |
| 19 | 11323675 | IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. | Nature | 2001 | https://conductscience.org/library/papers/11323675 | PubMed |
| 20 | 16984998 | Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16984998 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42568362 | Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies. | Front Oncol | 2026 | https://conductscience.org/library/papers/42568362 | PubMed |
| 42230788 | Hallmarks and correlates of effective adoptive cell immunotherapy for cancer. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/42230788 | PubMed |
| 37731507 | Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment. | Front Immunol | 2023 | https://conductscience.org/library/papers/37731507 | PubMed |
| 36125618 | Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. | Curr Treat Options Oncol | 2022 | https://conductscience.org/library/papers/36125618 | PubMed |
| 36124553 | Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. | Elife | 2022 | https://conductscience.org/library/papers/36124553 | PubMed |
| 35883486 | MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. | Biomolecules | 2022 | https://conductscience.org/library/papers/35883486 | PubMed |
| 32220256 | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. | J Transl Med | 2020 | https://conductscience.org/library/papers/32220256 | PubMed |
| 31492199 | Tumor neoantigens: from basic research to clinical applications. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31492199 | PubMed |
| 31413920 | Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/31413920 | PubMed |
| 30233579 | Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. | Front Immunol | 2018 | https://conductscience.org/library/papers/30233579 | PubMed |
| 28534024 | Cancer Immunoprevention and Public Health. | Front Public Health | 2017 | https://conductscience.org/library/papers/28534024 | PubMed |
| 26241053 | From mice to humans: developments in cancer immunoediting. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26241053 | PubMed |
| 24531241 | New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. | Curr Opin Immunol | 2014 | https://conductscience.org/library/papers/24531241 | PubMed |
| 24349875 | HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma. | Oncoimmunology | 2013 | https://conductscience.org/library/papers/24349875 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CTAG1A | 246100 | PubTator's text mining | https://conductscience.org/library/genes/246100 | NCBI Gene |
| MAGEC1 | 9947 | PubTator's text mining | https://conductscience.org/library/genes/9947 | NCBI Gene |
| MLANA | 2315 | PubTator's text mining | https://conductscience.org/library/genes/2315 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23882157
GET https://conductscience.org/api/papers/v1/23882157/references?page=2